Antifibrinolytics
Key Points
- Antifibrinolytics prevent the breakdown of fibrin clots by blocking plasmin activity, thereby slowing or stopping pathological hemorrhage.
- The two primary agents are tranexamic acid (TXA) and aminocaproic acid; TXA is more commonly used in clinical settings including postpartum hemorrhage and trauma.
- TXA is contraindicated in clients with active intravascular clotting due to the risk of thromboembolic complications.
- In postpartum hemorrhage (PPH), TXA 1 g IV over 10 minutes is administered within 3 hours of birth in conjunction with a uterotonic agent.
- Antifibrinolytics are also used as a reversal strategy when excessive bleeding occurs from thrombolytic therapy.
Mechanism of Action
The fibrinolytic system normally degrades blood clots after healing has occurred. Plasmin — an enzyme derived from plasminogen — cleaves fibrin within a clot to dissolve it. In conditions of pathological or excessive bleeding, this process can be counterproductive.
Antifibrinolytic agents work by inhibiting plasmin or plasminogen, thereby blocking the breakdown of fibrin clots and stabilizing hemostasis:
- Tranexamic acid (TXA): Synthetic lysine analogue that competitively blocks lysine-binding sites on plasminogen, preventing plasmin from attaching to and degrading fibrin.
- Aminocaproic acid: Similar mechanism — inhibits plasminogen activation and plasmin activity; used primarily in controlled surgical or bleeding settings.
Indications
| Indication | Primary Agent | Notes |
|---|---|---|
| Postpartum hemorrhage (PPH) | Tranexamic acid (TXA) | Given within 3 hours of birth alongside uterotonics |
| Trauma hemorrhage | Tranexamic acid | Early administration (within 3 hours of injury) reduces mortality |
| Surgical bleeding | Aminocaproic acid or TXA | Cardiothoracic, orthopedic, and other high-bleeding-risk procedures |
| Thrombolytic-induced excessive bleeding | TXA or aminocaproic acid | Reversal adjunct when tPA or streptokinase causes excessive hemorrhage |
| Hemophilia or coagulation factor deficiencies | Aminocaproic acid | Adjunctive support to factor replacement therapy |
Dosing and Administration
Tranexamic acid (TXA) in PPH:
- Usual dose: 1 g in 100 mL IV fluid administered over 10 minutes
- Must be given within 3 hours of birth for efficacy
- Prescribed in conjunction with a uterotonic (e.g., oxytocin, methylergonovine, carboprost)
Administration precautions:
- Administer via a dedicated IV line; avoid rapid infusion, which can cause hypotension and nausea.
- Dilute in normal saline or dextrose per institutional protocol.
Nursing Assessment
NCLEX Focus
Know the contraindication of antifibrinolytics in active intravascular clotting — giving TXA when clots are already forming pathologically (e.g., DIC) can worsen thrombotic events. This is a priority safety distinction on NCLEX.
- Assess for active intravascular clotting (e.g., disseminated intravascular coagulation [DIC]) before administration — TXA is contraindicated in this setting.
- Assess current hemostatic status: coagulation studies (PT, PTT, INR, fibrinogen, D-dimer) and signs of active hemorrhage versus thrombotic activity.
- Evaluate baseline neurological status and visual acuity, as TXA can cause visual disturbances and seizures.
- Assess history of thromboembolic events (DVT, PE, stroke) — antifibrinolytics increase thromboembolic risk.
Nursing Interventions
- Administer TXA within 3 hours of hemorrhagic event (birth, injury, or surgery onset) for maximum efficacy; delayed administration significantly reduces benefit.
- Monitor the client continuously for signs of:
- Thromboembolic complications: unilateral limb pain/swelling (DVT), sudden dyspnea or chest pain (PE), sudden neurological changes (stroke)
- Seizures: new-onset twitching, altered consciousness, or postictal state
- Visual disturbances: blurred vision, color perception changes, or sudden vision loss
- Adverse GI effects: nausea, vomiting, diarrhea
- In PPH management, administer TXA in conjunction with uterotonic medications (oxytocin, carboprost); it is not a standalone treatment.
- If DIC is present or suspected, follow obstetric critical-care protocol and specialist direction because risk-benefit decisions for TXA can vary by trigger cause and active clotting profile.
- When used after thrombolytic therapy (e.g., alteplase), monitor for re-thrombosis versus persistent hemorrhage and titrate response accordingly.
Contraindication in Active Intravascular Clotting
Antifibrinolytics stabilize existing clots and prevent fibrinolysis. In DIC or other conditions with pathological intravascular clot formation, administration of TXA or aminocaproic acid can worsen clotting cascades, leading to end-organ damage from microvascular thrombosis. Confirm absence of active intravascular clotting before administration.
Adverse Effects
| Adverse Effect | Clinical Significance |
|---|---|
| Thromboembolic events (DVT, PE, stroke) | Most serious; increased risk in predisposed clients |
| Seizures | Dose-dependent; monitor neurologically |
| Visual disturbances | Blurred vision, color changes; discontinue if acute |
| Nausea, vomiting, diarrhea | Common; manage with antiemetics |
| Hypotension | With rapid IV infusion; administer slowly |
Related Concepts
- hemostasis-coagulation-and-fibrinolysis — Normal coagulation cascade and fibrinolytic pathway targeted by antifibrinolytics.
- postpartum-hemorrhage — Primary obstetric indication for TXA within 3 hours of birth.
- uterotonics — Concurrent pharmacologic management in PPH alongside TXA.
- blood-transfusion-verification-initiation-and-reaction-response — Blood product administration as a co-intervention in major hemorrhage.
- hypersensitivity-types-and-anaphylaxis-response — Risk of hypersensitivity reactions with antifibrinolytics.
Self-Check
- What is the mechanism by which tranexamic acid (TXA) reduces hemorrhage, and why is this mechanism effective in postpartum hemorrhage?
- A postpartum client with suspected DIC is actively bleeding. Why would TXA be contraindicated in this scenario?
- What is the recommended dose and time window for TXA administration in postpartum hemorrhage, and why must it be given alongside a uterotonic?